<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534764</url>
  </required_header>
  <id_info>
    <org_study_id>CR-6060</org_study_id>
    <nct_id>NCT04534764</nct_id>
  </id_info>
  <brief_title>Evaluation of Visual Performance of Two Types of Cosmetic Contact Lenses</brief_title>
  <official_title>Evaluation of Visual Performance of Two Types of Cosmetic Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single visit, brand-masked, non-dispensing, 2×2 bilateral crossover study. Each&#xD;
      subject will be bilaterally fitted with one of the two test articles in each of the study&#xD;
      periods in a random order with a 5-minute washout period in between study lenses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2020</start_date>
  <completion_date type="Actual">August 12, 2020</completion_date>
  <primary_completion_date type="Actual">August 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distance Monocular Visual Acuity (logMAR)</measure>
    <time_frame>5 min post lens insertion</time_frame>
    <description>Visual acuity on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters) under high luminance low contrast and low luminance high contrast lighting conditions using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. Letter-by letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Visual Acuity</condition>
  <arm_group>
    <arm_group_label>TEST/CONTROL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects that are habitual soft contact lens wearers will be randomized into lens wear sequence (Test/Control)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL/TEST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects that are habitual soft contact lens wearers will be randomized into lens wear sequence (Control/Test)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A with cosmetic pattern</intervention_name>
    <description>TEST</description>
    <arm_group_label>CONTROL/TEST</arm_group_label>
    <arm_group_label>TEST/CONTROL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1-Day Acuvue DEFINE Vivid Style</intervention_name>
    <description>CONTROL</description>
    <arm_group_label>CONTROL/TEST</arm_group_label>
    <arm_group_label>TEST/CONTROL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Potential subjects must satisfy all of the following criteria to be enrolled in the&#xD;
             study:&#xD;
&#xD;
               1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and&#xD;
                  receive a fully executed copy of the form&#xD;
&#xD;
               2. Appear able and willing to adhere to the instructions set forth in this clinical&#xD;
                  Protocol.&#xD;
&#xD;
               3. Subjects between 18 and 39 (inclusive) years of age at the time of screening&#xD;
&#xD;
               4. Be a current soft contact lens wearer in both eyes with a minimum of 6 hours/day&#xD;
                  and 5 days/week over the last month by self-report.&#xD;
&#xD;
               5. The subject must be willing to be photographed and/or video-taped.&#xD;
&#xD;
               6. The subject's vertex corrected spherical equivalent distance refraction must be&#xD;
                  in the range of -1.00 D to -6.00 D (inclusive) in each eye&#xD;
&#xD;
               7. The subject's refractive cylinder must be less than or equal to 0.75 D&#xD;
                  (inclusive) in each eye.&#xD;
&#xD;
               8. Have spherical best corrected visual acuity of 20/25 or better in each eye.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  Potential subjects who meet any of the following criteria will be excluded from&#xD;
             participating in the study:&#xD;
&#xD;
               1. Currently pregnant or lactating&#xD;
&#xD;
               2. Any systemic disease (eg, Sjögren's Syndrome), allergies, infectious disease (eg,&#xD;
                  hepatitis, tuberculosis), contagious immunosuppressive diseases (eg, HIV),&#xD;
                  autoimmune disease (eg rheumatoid arthritis), or other diseases, by self-report,&#xD;
                  which are known to interfere with contact lens wear and/or participation in the&#xD;
                  study (at the investigators discretion).&#xD;
&#xD;
               3. Use of systemic medications (eg, chronic steroid use) that are known to interfere&#xD;
                  with contact lens wear (at the investigators discretion)&#xD;
&#xD;
               4. Any previous, or planned (during the study) ocular surgery (eg, radial&#xD;
                  keratotomy, PRK, LASIK, etc.)&#xD;
&#xD;
               5. Participation in any contact lens or lens care product clinical trial within&#xD;
                  seven (7) days prior to study enrollment&#xD;
&#xD;
               6. Employee or family members of clinical site (eg, Investigator, Coordinator,&#xD;
                  Technician).&#xD;
&#xD;
               7. Any ocular allergies, infections or other ocular abnormalities that are known to&#xD;
                  interfere with contact lens wear and/or participation in the study. This may&#xD;
                  include, but not be limited to entropion, ectropion, extrusions, chalazia,&#xD;
                  recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or&#xD;
                  corneal distortion (at the investigators discretion).&#xD;
&#xD;
               8. Clinically significant (Grade 3 or 4 on FDA scale) tarsal abnormalities, bulbar&#xD;
                  injection, corneal edema, corneal vascularization, corneal staining, or any other&#xD;
                  abnormalities of the cornea which would contraindicate contact lens wear.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maitland Vision Center</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <results_first_submitted>August 6, 2021</results_first_submitted>
  <results_first_submitted_qc>August 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 1, 2021</results_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu</ipd_description>
    <ipd_url>http://yoda.yale.edu</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT04534764/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 35 subjects were enrolled in this study. Of those enrolled, all 35 subjects were dispensed both study lenses and completed the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Test/Control</title>
          <description>Subjects randomized to receive the Test lens during the first period and then received the Control lens during the second period.</description>
        </group>
        <group group_id="P2">
          <title>Control/Test</title>
          <description>Subjects randomized to receive the Control lens during the first period and then received the Test lens during the second period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total</title>
          <description>All subjects who had successfully completed all visits and did not substantially deviate from the protocol.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.2" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Distance Monocular Visual Acuity (logMAR)</title>
        <description>Visual acuity on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters) under high luminance low contrast and low luminance high contrast lighting conditions using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. Letter-by letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.</description>
        <time_frame>5 min post lens insertion</time_frame>
        <population>All subjects who had successfully completed all visits and did not substantially deviate from the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>Subjects that wore the Test lens in either the first or second period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects that wore the Control lens in either the first or second period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Distance Monocular Visual Acuity (logMAR)</title>
          <description>Visual acuity on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters) under high luminance low contrast and low luminance high contrast lighting conditions using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. Letter-by letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.</description>
          <population>All subjects who had successfully completed all visits and did not substantially deviate from the protocol.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High Luminance Low Contrast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.016" spread="0.1083"/>
                    <measurement group_id="O2" value="-0.001" spread="0.1046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Luminance High Contrast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.171" spread="0.0857"/>
                    <measurement group_id="O2" value="-0.151" spread="0.0852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Luminance High Contrast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016" spread="0.1008"/>
                    <measurement group_id="O2" value="0.007" spread="0.0814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>High Luminance Low Contrast</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority of the Test lens relative to the Control will be concluded if the upper confidence limit of LSM difference is below the non-inferiority margin 0.05 logMAR.</non_inferiority_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-0.016</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0114</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.006</ci_upper_limit>
            <estimate_desc>LS Mean difference was calculated as Test - Control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Low Luminance High Contrast</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority of the Test lens relative to the Control will be concluded if the upper confidence limit of LSM difference is below the non-inferiority margin 0.05 logMAR.</non_inferiority_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.009</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0114</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.014</ci_lower_limit>
            <ci_upper_limit>0.031</ci_upper_limit>
            <estimate_desc>LS Mean difference was calculated as Test - Control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the duration of the study. Approximately 1 day per subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test</title>
          <description>Subjects that wore the Test lens in either the first or second period of the study.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Subjects that wore the Control lens in either the first or second period of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Meredith Bishop, OD, MS, FAAO-Sr. Principal Research Optometrist</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care</organization>
      <phone>904-443-1783</phone>
      <email>mbishop4@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

